Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Immunotech Biopharm Ltd (6978)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.16 -0.02    -0.63%
08/05 - Closed. Currency in HKD ( Disclaimer )
  • Volume: 40,000
  • Bid/Ask: 3.16 / 3.25
  • Day's Range: 3.10 - 3.29
Type:  Equity
Market:  Hong Kong
ISIN:  KYG4721A1004 
Immunotech 3.16 -0.02 -0.63%

Immunotech Biopharm Ltd Company Profile

 
Get an in-depth profile of Immunotech Biopharm Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

246

Equity Type

ORD

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for non-hodgkin lymphoma; and TCR-T cell series products to treat solid tumors. Further, the company’s pre-clinical products include aT19 to treat acute lymphoblastic leukaemia; CAR-T-43 for T cell leukaemia and T cell lymphoma; CAR-T-22 for B lymphocyte leukaemia; CAR-T-BCMA to treat multiple myeloma; CAR-T-ENX for solid tumors; TCR800 to treat renal cancer; and EBV, CMV specific T cells for EBV/CMV infection. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People’s Republic of China.

Contact Information

Address Guosheng Technology Park 8th Floor, Block 1
No.1 Kangding Street Beijing Eco-Tech Dev Area Beijing,
China
Phone -
Fax 86 10 8840 0152

Top Executives

Name Age Since Title
Zheng Tan - - Executive Chairman
Yuezhong Li - - Non-Executive Director
Chi Kit Ng 49 2020 Independent Non-Executive Director
Yingdian Wang 61 2020 Independent Non-Executive Director
Donghu Wang 69 2023 Non-Executive Director
Sujiu Peng 44 2020 Independent Non-Executive Director
Ran Tao 58 2021 Non-Executive Director
Fan Yang 42 2023 Non-Executive Director
Ruihua Wang 59 2023 Non-Executive Director
Yu Wang 56 2018 CEO, CTO & Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

6978 Comments

Write your thoughts about Immunotech Biopharm Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email